FinancialBuzz.com’s latest
The Buzz
Show: Featuring Our Corporate News Recap on “ Cellect Biotechnology Ltd.
Announces First ApoGraft Transplantation in U.S. Patient
”
Cellect Biotechnology Ltd. (NASDAQ: APOP)
surged over 61% in premarket trading after the company announced the first ApoGraft transplantation in a Leukemia patient in the Company’s clinical trial at Washington University in the U.S.
ApoGraft is a product based on the Company’s cell selection technology designed to optimize immune therapy, and the recruitment of the patient provides momentum to commence funding for the technology under the US entity, EnCellX
.
Cellect Biotechnology (APOP) has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims to improve a variety of cell-based therapies.
The Company’s technology is expected to provide researchers, clinical community, and pharma companies with the tools to rapidly isolate specific cells in quantity and quality allowing cell-based treatments and procedures in a wide variety of applications in regenerative medicine. The Company’s current clinical trial is aimed at bone marrow transplantations in cancer treatment.
For more information, please visit:
Cellect Biotechnology Ltd.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.
The post
“The Buzz” Show: Cellect Biotechnology Ltd. (NASDAQ: APOP) ApoGraft Transplantation in U.S. Patient
first appeared on
Financial Buzz
.
For further details see:
“The Buzz” Show: Cellect Biotechnology Ltd. (NASDAQ: APOP) ApoGraft Transplantation in U.S. Patient